Clinical Study Results

Research Sponsor: Pearl Therapeutics, Inc.

Drug Studied: Glycopyrronium inhalation aerosol, also called GP MDI or PT001

Study Title: A study to learn how different doses of GP MDI affected participants with asthma

Thank you!

Thank you to the participants who took part in the clinical study for the study drug glycopyrronium inhalation aerosol, also called PT001 or GP MDI. All of the participants helped researchers learn more about GP MDI to help people who have asthma.

Pearl Therapeutics, Inc sponsored this study and thinks it is important to share the results of the study with the public. An independent non-profit organization called CISCRP helped prepare this summary of the study results.

If you participated in the study and have questions about the results, please speak with the doctor or staff at your study site.

What is happening with the study now?

The participants were in the study for up to 7 months, but the entire study took 22 months to finish. The study started in December 2017 and ended in September 2019.

This study included a total of 1,077 participants in the United States.

The sponsor reviewed the data collected when the study ended and created a report of the results. This is a summary of that report.